InnoCan Pharma Corporation
INNO
CNSX
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -2.63% | -10.13% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -2.63% | -10.13% | |||
| Cost of Revenue | -22.19% | 19.09% | |||
| Gross Profit | -0.06% | -12.93% | |||
| SG&A Expenses | 24.38% | -12.77% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 21.63% | -9.54% | |||
| Operating Income | -407.58% | -19.02% | |||
| Income Before Tax | -1,213.76% | -430.30% | |||
| Income Tax Expenses | 6.80% | -21.37% | |||
| Earnings from Continuing Operations | -424.44% | -37.55% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -7.27% | 22.10% | |||
| Net Income | -230.00% | -1.37% | |||
| EBIT | -407.58% | -19.02% | |||
| EBITDA | -398.02% | -18.84% | |||
| EPS Basic | -229.88% | -0.69% | |||
| Normalized Basic EPS | -288.35% | 14.65% | |||
| EPS Diluted | -229.88% | -0.69% | |||
| Normalized Diluted EPS | -288.35% | 14.65% | |||
| Average Basic Shares Outstanding | 0.06% | 0.66% | |||
| Average Diluted Shares Outstanding | 0.06% | 0.66% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||